Navigation Links
Stent in Medical News

CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System

Advanced Platinum Surface Maximizes Biocompatibility and Biostabilityin a Bare-Metal Stent BURLINGTON, Mass., June 23 /PRNewswire/ -- CorNova Inc. today announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System. (Logo: http://www.newscom.com/...

Newest Coated Stent Does Well in Real-World Trial

Safe and effective in an 'all-comer population,' researchers say WEDNESDAY, June 17 (HealthDay News) -- The newest drug-coated stent has performed well in a real-life trial, Dutch cardiologists report. The Xience stent -- a flexible metal-mesh tube coated with the drug everolimus --...

Broncus Technologies' Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group

WALTHAM, Mass., June 16 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the rise in the US prevalence of emphysema is prompting device firms to develop endoscopic devices used to diagnose or treat the condition. Curre...

XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration

MENLO PARK, Calif., June 4 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical pro...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

Safety and Efficacy Rates in Patients with Challenging Anatomy Consistent with Superior Results from Randomized Clinical Trials BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at EuroPCR from an international, post-approval, single-arm study show that Abbott's mark...

SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

NATICK, Mass. and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System. ...

Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease

MOBILITY trial showcases company's leadership in developing innovative endovascular treatment options ABBOTT PARK, Ill., April 1 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro(T...

XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System

60 millimeter Custom NX 60 is the world's longest coronary stent to ever be approved MENLO PARK, Calif., March 19 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that it has received CE Mark approval for its CUSTOM NX drug-eluting stent (DES) System. The CE Mark indic...

Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System

Japanese patients now have access to second-generation drug-eluting stent NATICK, Mass., March 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System in Japan. The product was app...

Blood Flow Measurement Boosts Stent Outcomes

Technology reduces deaths, complications, but may be too costly for some centers, experts say WEDNESDAY, Jan. 14 (HealthDay News) -- A sophisticated measure of blood flow to determine where artery-opening stents should be implanted is more effective than the X-ray examinations now comm...

Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin

NEW YORK (Dec. 17, 2008) The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. The work by researchers...

Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels

ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treat...

New Type of Stent Shows Promise

It recruits blood vessel cells as a kind of heart-healthy coating, experts explain TUESDAY, Nov. 11 (HealthDay News) -- A new generation of stents shows promise in avoiding the late-onset problems that have plagued drug-eluting stents in patients with heart disease, researchers say. ...

MDCT: Non-invasive alternative to bronchoscopy in patients with airway stent complications

Multidetector CT (MDCT) scans are highly accurate in detecting airway stent complications according to a recent study performed at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, MA. MDCT correctly identified 29 (97%) of 30 complications in 21 patients, including all...

Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter

TAXUS(R) Atom(TM) in more than 500 accounts Company opening new PROMUS(TM) accounts NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced estimated U.S. market shares for September for its two drug-eluting ste...

New Type of Stent Appears Safe, Effective

Artery-opening device emits drug from a biodegradable polymer MONDAY, Sept. 1 (HealthDay News) -- One of a "new generation" of artery-opening, drug-eluting stents appears equally effective as older models in boosting outcomes for heart patients, a new head-to-head study shows. Stent...

How to use endoscopic stent for biliary stricture trauma?

Biliary stricture after blunt abdominal trauma is an extremely rare condition. There is no definitive treatment for a biliary stricture caused by blunt abdominal trauma. Nonsurgical intervention, especially endoscopic treatment has recently been used and has shown promising results. This case,...

Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan

Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting Stent TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced that it has submitted an application for Seizo Hanbai Shonin (Marketing Authorization L...

High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets

Procedural growth could increase by more than 20% over the next five years, according to Millennium Research Group WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the thoracic aortic sten...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program

NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS(R) Express2(TM...

New Drug-Coated Stent Does Well in Early Trial

But doctors want more data, and device not yet approved for use in U.S. TUESDAY, April 22 (HealthDay News) -- A new kind of drug-coated stent was better at keeping arteries open than an older stent in the first large-scale U.S. study of the device, researchers report. "This study su...

Melt-Away Stent Works Well in Trial

Absorbed harmlessly in the body, it could replace traditional metal stents THURSDAY, March 13 (HealthDay News) -- A polymer stent that is quietly absorbed by the body after it has done its job of keeping a coronary artery open has worked well in an international trial, researchers repo...

NIH report on intracranial stent points out need for upcoming large-scale clinical trial

LOS ANGELES (Feb. 13, 2008) A preliminary study funded by the National Institutes of Health found that a stent designed to open clogged arteries in the brain was successfully deployed in nearly all cases and significantly reduced arterial blockage in the short term. But data on the long-term bene...

Half of patients undergoing cerebrovascular stent placement respond poorly to clopidogrel

(CHICAGO) A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medicatio...

Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart Arteries

Avoids Deadly Clotting Problems of Drug-Eluting Stents HOLLYWOOD, Fla., Jan. 21 /PRNewswire/ -- A new stent with a nanothin surface application shows promise in opening and healing blocked heart arteries without the life-threatening dangers of drug-eluting stents, according to a study...

'Drug-Free' Stent Coating Shows Promise

Trial finds polymer reduces inflammatory reaction associated with current devices MONDAY, Jan. 21 (HealthDay News) -- A new kind of coated stent holds promise for overcoming the major problems with these tubes that are inserted to keep arteries open after clot-clearing angioplasty, Ita...

XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe

- Company continues U.S. pivotal trial discussions with FDA - MENLO PARK, Calif., Dec. 27 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ), the developer of customizable drug-eluting stent (DES) systems, today announced that it has submitted its application to the designated Europea...

TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients

TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent NATICK, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) announced today that its TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system...

Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions

- Five hundred patients treated with company's AXXESS(TM) System to date - LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- Devax, Inc., a medical device company focused on developing next generation products for interventional cardiology, today announced that the Company has completed patient enro...

FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-genera...

Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System

NATICK, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the recommendation of a U.S. Food and Drug Administration (FDA) advisory panel to approve with conditions the PROMUS(TM) / XIENCE(TM) V everolimus-eluting coronary stent system. The PROM...

LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System

BURLINGTON, Mass., Nov. 16 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT ) today announced the commercial launch of the TT(TM) Tortuous Tracker Delivery System, the next-generation introducer for LeMaitre Vascular's EndoFit(R) and UniFit(TM) Aortic Stent Graft product lines....

FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent

NATICK, Mass., July 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS((R)) Liberte((R)) Long Paclitaxel-Eluting Coronary Stent System, a next-generation d...

AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent

PARKERS PRAIRIE, Minn., July 6 /PRNewswire/ -- AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to...

NYC first: Complex aneurysm treated using new fenestrated endograft stent

NEW YORK (July 07, 2008) -- In a New York City metro-area first, a 93-year-old Bronx man underwent implantation of a new stent graft at NewYork-Presbyterian Hospital, the only center on the Eastern Seaboard with access to this investigational device. The new stent graft was implanted under an FDA...

Registry unveils 'real-world' data on novel excel stent

CHICAGO, Ill. (March 31, 2008) Real-world use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry. Results of the CREATE study, which focused on the sirolimus-eluting Excel sten...

Spirit II explores long-term performance of XIENCE V stent

CHICAGO, Ill. (March 31, 2008) Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-...

The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent

ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-t...

Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent

New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting Coronary ...

ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall sa...
Other Tags
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers , a company ... The company is currently offering lice head checks for just $10, which is a ... a 10% discount on their lice treatment products. “With kids returning to school, it ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... Jeff Fernandez will lead the expansion of global cosmeceutical and skin care brands. ... experience having spent the last 25 years working in operations, purchasing and management ...
(Date:8/29/2015)... ... 30, 2015 , ... Electronic Informed Consent for Clinical Trials:, ... EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed consent is ... Clinical trial sites can now use audio, video and interactivity to educate participants ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
Other Contents